<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360956</url>
  </required_header>
  <id_info>
    <org_study_id>S2014-119-01</org_study_id>
    <nct_id>NCT02360956</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)</brief_title>
  <official_title>Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether olmesartan medoxomil is effective in the
      treatment of coronary atherosclerosis progression and epicardial adipose tissue(EAT) volume
      reduction in patients with coronary atherosclerosis detected by coronary CT
      angiography(CCTA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epicardial adipose tissue(EAT) is directly deposited around the pericardium and coronary
      artery. By means of paracrine action, it can generate various kinds of cytokines,
      inflammatory factor and free fatty acids, that can affect the state of coronary endothelial
      function, inflammation and oxidative stress, which finally aggravate the progression of
      coronary atherosclerosis. In recent years, clinical studies have shown that EAT is a newly
      discovered independent risk factor of coronary atherosclerosis.Studies confirm that
      olmesartan medoxomil can improve endothelial function, resisting thrombosis, improve tissue
      reconstruction, resisting oxidative stress so as to achieve atherosclerosis resistant. Latest
      researches show that olmesartan medoxomil can better inhibit rat epididymal adipose cell
      hypertrophy and inflammatory reaction. Coronary CT angiography(CCTA) has emerged as a
      noninvasive imaging method for analysis coronary atherosclerosis. The purpose of this study
      is to determine whether olmesartan medoxomil is effective in the treatment of coronary
      atherosclerosis progression and EAT volume reduction in patients with coronary
      atherosclerosis detected by CCTA.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary atherosclerosis progression detected by CCTA</measure>
    <time_frame>12 month</time_frame>
    <description>Coronary atherosclerosis progression is defined as ≥10% diameter reduction or progression of a pre-existing coronary stenosis; or ≥0.2mm reduction or progression of the minimal luminal area (MLD) in the lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epicardial Adipose Tissue(EAT) volume detected by CCTA</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship between coronary atherosclerosis and EAT, as indicated by coronary atherosclerosis progression and epicardial adipose tissue(EAT) volume changes</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of blood lipids</measure>
    <time_frame>12 month</time_frame>
    <description>Blood lipids include total cholesterol,triglyceride,high density lipoprotein(HDL) and low density lipoprotein(LDL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of blood glucose</measure>
    <time_frame>12 month</time_frame>
    <description>Blood glucose is defined as fasting blood glucose(FBG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating surrogate markers of atherosclerosis inflammation including hs-CRP,IL-6,MCP-1,TNF--α and MMP-9</measure>
    <time_frame>12 month</time_frame>
    <description>CRP: C reactive protein; IL: Interleukin; MCP: Monocyte chemotactic protein,composite of chemoattractant markers; TNF-α: tumor necrosis factor; MMP: Matrix metalloproteinase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual circulating surrogate markers of endothelial function including NO and ET-1</measure>
    <time_frame>12 month</time_frame>
    <description>ET: Endothelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual circulating surrogate markers of adipose tissue inflammation and metabolism including adiponectin and leptin.</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antihypertensive medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).
The drug dose must be individualized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil tablets</intervention_name>
    <description>Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <other_name>Benicar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive medication (per doctor suggestion)</intervention_name>
    <description>Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.</description>
    <arm_group_label>Antihypertensive medication</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery stenosis between 30% and 70% determined by CCTA in essential
             hypertension patients

          -  resting diastolic blood pressure (DBP) between 90 and 110 mmHg

          -  type A and B for coronary artery vascular lesions

        Exclusion Criteria:

          -  secondary hypertension

          -  coronary artery stenosis less than 30% or greater than 70% determined by CCTA

          -  contraindications to treatment with olmesartan medoxomil (allergy, glaucoma, digestive
             ulcer, is currently taking phosphodiesterase-5 inhibitor)

          -  resting systolic blood pressure (SBP) ＞ 200 mmHg or resting diastolic blood pressure
             (DBP) ＞ 110 mmHg

          -  Severe calcification, distortion or type C for coronary artery vascular lesions

          -  pregnancy

          -  unwillingness or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yundai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Ying</last_name>
    <phone>86-15810836908</phone>
    <email>zhouying0129@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yundai</last_name>
      <phone>86-10-55499246</phone>
      <email>cyundai301@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Alexopoulos N, McLean DS, Janik M, Arepalli CD, Stillman AE, Raggi P. Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis. 2010 May;210(1):150-4. doi: 10.1016/j.atherosclerosis.2009.11.020. Epub 2009 Nov 20.</citation>
    <PMID>20031133</PMID>
  </reference>
  <reference>
    <citation>Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab. 2012 Oct 15;303(8):E937-49. doi: 10.1152/ajpendo.00061.2012. Epub 2012 Aug 14. Review.</citation>
    <PMID>22895783</PMID>
  </reference>
  <reference>
    <citation>Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5(1):301-14. Epub 2009 Apr 8. Review.</citation>
    <PMID>19436655</PMID>
  </reference>
  <reference>
    <citation>Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kanaoka T, Kobayashi R, Ohki K, Matsuda M, Tsurumi-Ikeya Y, Yamashita A, Tokita Y, Umemura S. Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders. Biomed Res Int. 2014;2014:946492. doi: 10.1155/2014/946492. Epub 2014 Jun 2.</citation>
    <PMID>24991574</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yundai Chen</investigator_full_name>
    <investigator_title>Director of Cardiology,People's Liberation Army General Hospital</investigator_title>
  </responsible_party>
  <keyword>Olmesartan medoxomil</keyword>
  <keyword>Epicardial adipose tissue</keyword>
  <keyword>Multidetector Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

